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(G. Cecchini).Alkaline incubation of NADH results in the formation of a very potent inhibitor of lactate dehydro-
genase. High resolution mass spectroscopy along with NMR characterization clearly showed that the
inhibitor is derived from attachment of a glycolic acid moiety to the 4-position of the dihydronico-
tinamide ring of NADH. The very potent inhibitor is competitive with respect to NADH. The inhibitor
added in submicromolar concentrations to cardiomyocytes protects them from damage caused by
hypoxia/reoxygenation stress. In isolated mouse hearts, addition of the inhibitor results in a sub-
stantial reduction of myocardial infarct size caused by global ischemia/reperfusion injury.
Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction genase (LDH). They originate from modiﬁcation of the nicotin-For many years analogues of NAD+/NADH have proven valuable
in studies of the binding of the pyridine coenzyme and mechanism
of dehydrogenases which utilize these cofactors [1]. Recently, it
was demonstrated that incubation of NADH in oxygen saturated
alkaline solutions results in the formation of a very strong compet-
itive inhibitor of mitochondrial complex I (NADH:ubiquinone oxi-
doreductase) [2]. Many NAD+/NADH derivatives may act as
alternative substrates or competitive inhibitors of lactate dehydro-lf of the Federation of European Bi
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yar), Gary.Cecchini@ucsf.eduamide ring of the dinucleotide at positions C-3, C-4, or C-5 [1,3–
5]. These compounds were shown to act as competitive inhibitors
with respect to NADH and were capable of inhibiting both LDH and
malate dehydrogenase (MDH). Other dehydrogenases such as alco-
hol dehydrogenase, glyceraldehyde-3-phosphate dehydrogenase,
glycerate dehydrogenase, and glycerol dehydrogenase were only
slightly suppressed by the NADH derivatives [5]. It has been dem-
onstrated that incubation of LDH in the presence of pyruvate and
NAD+ results in the formation of a strong inhibitor (nicotinamide
adenine dinucleotide-pyruvate, NAD-Pyr) in the active center of
the enzyme. In NAD-Pyr the b-carbon atom of pyruvate is cova-
lently linked to the C-4 position of the nicotinamide ring [6–8].
The NAD- and 3-substituted NAD (3-acetylpyridine nicotinamide
adenine dinucleotide, APAD) pyruvate adducts also spontaneously
form during the incubation of pyruvate and the dinucleotides at pH
11 [9,10]. Addition of these adducts to LDH results in strong sup-
pression of enzyme activity [11,12]. These adducts are, however,
relatively unstable at neutral pH and rapidly decompose into pyru-
vate and NAD or APAD [9,12].
During ischemia cells produce high intracellular levels of lactic
acid. In ischemic tissues glycolysis provides the main source of ATP
for the cell. The ﬁnal product of glycolysis, pyruvate, can not beochemical Societies.
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converted to lactate by LDH. The latter reaction leads to the accu-
mulation of lactic acid and to the associated lowering of intracellu-
lar pH. It has been proposed that the decrease in pH caused by
lactic acid accumulation may be a major cause of severe ischemic
brain and heart injury [13–16]. The key role of LDH in the above
process stimulated the development of speciﬁc inhibitors of the
enzyme, which could prevent the production of lactic acid and thus
protect tissues from lactic acidosis. It has been shown that reduced
APAD-Pyr strongly decreases lactate production in crude brain ex-
tracts [9]. It was, however, much less effective at inhibiting lactate
production in synaptosomes. The main reason for a weaker effect
on lactate production in vivo is likely associated with the low sta-
bility of the inhibitor at physiological pH [12]. This is a serious dis-
advantage that limits the use of NAD-Pyr and APAD-pyr adducts
for preventing lactic acidosis induced damage in vivo.
In this work a novel NADH derived inhibitor of LDH was pre-
pared and its molecular structure characterized. It is shown that
the inhibitor is very strong and competitive with respect to NADH.
The inhibitor also reduces myocardial infarct size following ische-
mia/reperfusion (I/R) injury in mouse heart and protects cultured
adult mouse cardiomyocytes from damage induced by hypoxia/
reoxygenation. The mechanism of the cardioprotective effect of
the LDH inhibitor is discussed.
2. Materials and methods
2.1. Preparation of the inhibitor
The crude inhibitor was produced from aerobic alkaline NADH
solutions by procedures similar to that that were used to produce
a previously described inhibitor of Complex I [2]. Initially 17.5 g
of NADH was dissolved in 500 ml of water in a 1 l capacity plastic
bottle with screw top. The bottle was placed on ice and 5 ml of
10 M KOH were added dropwise to the solution with constant
stirring at high speed. Then 500 ml of methanol was added and
the mixture saturated with oxygen by bubbling the pure gas
through the solution for 30 min at 4 C. The bottle was tightly
sealed and left in the dark at room temperature for 2 days. An in-
tense yellow color developed during the incubation. The solution
was diluted twice with double distilled water and applied to a
130 ml capacity Q-sepharose Fast Flow column previously equili-
brated with 5 mM potassium phosphate (K-Pi) (pH 12). Elution of
the inhibitor was at pH 12 with a linear 5–1000 mM K-Pi gradient
at a ﬂow rate of 2 ml/min. The fractions containing the inhibitor
eluted from the column after authentic NADH at approximately
400–450 mM K-Pi (see Supplementary Fig. S1). Fractions were
tested for their ability to suppress LDH activity. The inhibitor-
containing fractions were pooled and concentrated on a C-18 col-
umn as follows. The pH of the eluted solution was adjusted to 7.4
by adding 4 M HCl. The neutralized solution (200 ml) was ap-
plied to a column pre-packed with 20 g of C-18 silica-based ma-
trix column and equilibrated with 0.1 mM K-Pi (pH 7) and eluted
from the column in 20% methanol. In order to completely purify
the inhibitor we took advantage of the very strong afﬁnity of
the inhibitor to LDH. Therefore, the eluate containing crude inhib-
itor was mixed with an equal volume of a 5 mg/ml LDH solution
and incubated at 25 C for 30 min. The solution was transferred
into Centriprep YM-30 centrifugal ﬁlter units (Millipore, USA)
and LDH in complex with inhibitor was concentrated by centrifu-
gation at 1800g for 30 min at 4 C. The ﬁltrate was discarded;
the resulting concentrate was diluted 10-times by adding
0.1 M K-Pi (pH 7). The solution was then centrifuged a second
time. The concentrate obtained after four more separating spins
containing a complex of LDH with the inhibitor was collected.The volume of the fraction was adjusted to 10 ml by adding
0.1 M K-Pi (pH 7). 10 ml of 1 M K-Pi (pH 12) was then added to
the fraction and incubated for 10 min at room temperature. This
treatment leads to denaturation of LDH and to liberation of the
free inhibitor from the complex. The solution was transferred into
Centriprep YM-30 centrifugal ﬁlter units and centrifuged at
1800g for 30 min at 4 C. The concentrate containing denatured
LDH was discarded and the ﬁltrate containing the free inhibitor
was collected and used in this study. HPLC analysis of the isolated
inhibitor showed that it was chromatographically pure and the ﬁ-
nal yield was approximately 2 mg of inhibitor from the initial
17.5 g of NADH.
2.2. Enzyme assay
Each enzyme was assayed spectrophotometrically at 25 C in
0.1 M K-Pi (pH 7.0) buffer containing 0.1 mM EDTA. The change
of NADH absorbance at 340 nm (e340 = 6.22 mM1 cm1) was fol-
lowed. The enzyme assay systems also contain: LDH – 50 lM
NADH and 1 mM pyruvate; MDH – 150 lM NADH and 0.25 mM
oxaloacetate; alcohol dehydrogenase – 5 mM NAD+ and 3% etha-
nol; glutamate dehydrogenase – 150 lM NADH, 10 mM a-ketoglu-
tarate and 10 mM ammonium-acetate; DT diaphorase – 100 lM
NADH and 60 lM 2,3-dimethoxy-5-methyl-6-(3-methyl-2-bute-
nyl)-1,4-benzoquinone (Q1); NADH-oxidase – 100 lM NADH and
0.05 lg/ml of gramicidin D. Other details of the assays are indi-
cated in the ﬁgure legends. All reactions were initiated by the addi-
tion of enzymes listed below to the assay mixture. LDH (EC
1.1.1.27) from bovine heart and rabbit muscle, MDH (EC 1.1.1.37)
from porcine heart, alcohol dehydrogenase (EC 1.1.1.1) from
equine liver; glutamate dehydrogenase (EC 1.4.1.3) from bovine li-
ver were all from Sigma (USA). Human recombinant DT diaphorase
(EC 1.6.99.2) was prepared as described [17]. Bovine heart submi-
tochondrial particles (SMP) were prepared as described [18].
2.3. Absorption spectroscopy
Absorption measurements were carried out with an Agilent
8453 Diode Array Spectrophotometer (Agilent Technologies, USA).
2.4. High resolution mass spectroscopy
The high resolution mass spectroscopy (HRMS) estimation of
the molecular mass and the molecular formula of the inhibitor
were done by M-Scan Inc. (West Chester, PA, USA) using high res-
olution ESI-MS in the negative ion mode.
2.5. Nuclear magnetic resonance spectroscopy
NMR spectra were determined in D2O (Aldrich, Milwaukee,
USA). NMR spectra were recorded with Varian UnityINOVA
700 MHz and 500 MHz spectrometers. TOCSY spectra [19] were re-
corded with a mixing time of 80 ms. {1H–13C}-heteronuclear sin-
gle quantum coherence (HSQC) [20] and {1H–13C}-heteronuclear
multiple bond correlation (HMBC) [21] were optimized for 1JC–H =
135 Hz and 2,3JC–H = 10 Hz, respectively. HSQC and TOCSY experi-
ments were recorded using states-TPPI procedure for quadrature
detection. In all 2D experiments the time domain data consisted
of 2048 complex points in t2 and 400–512 ﬁds in t1 dimension.
The relaxation delay was kept at 1.2 s for all experiments. The
spectra were acquired at T = 5 C and calibrated relative to HDO
(4.96 ppm) as internal standard. The NMR data were processed
on a SGI Octane workstation using FELIX 98 software (Accelrys,
San Diego, USA) and on an iMAC using iNMR (www.inmr.net)
software.
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Ventricular myocytes were cultured as previously described
[22]. On the day after isolation and culture, cardiac myocytes were
subjected to 3 h of hypoxia (1% CO2 and 99% N2). Immediately after
hypoxia cells were treated with varying concentrations of NADH–
GA ranging from 10 nM to 1 lM during reoxygenation which
lasted for 16 h. Cardiac myocyte survival was measured as previ-
ously described [22] by staining cells in tissue culture dishes with
trypan blue solution.
2.7. Ischemia/reperfusion protocol
Hearts from male C57/Bl6 mice weighing 20–25 g were sub-
jected to 40 min of global ischemia and 45 min of reperfusion on
a Langendorff apparatus as previously described [23]. Hearts were
treated with vehicle (Krebs-Henseleit buffer) or NADH–GA infusion
at a concentration of 100 nM beginning at the end of ischemia and
lasting throughout reperfusion. Left ventricular pressures were re-
corded continuously throughout the experiment and infarct size
(triphenyltetrazolium method) was measured at the end of reper-
fusion as previously described [23].
2.8. Materials
All ﬁne chemicals used in this study were from Sigma–Aldrich.
3. Results
The exact molecular mass of the puriﬁed inhibitor prepared as
described in Section 2 was determined by high resolution electron
spray ionization mass spectral (HRESIMS) analysis in negative ion
mode. The puriﬁed inhibitor showed a single pseudomolecular
ion peak at m/z 738.1182 [(MH)] (data not shown). This mass
corresponds to a molecular formula of C23H30N7O17P2 suggestingTable 1
1H, 13C, and 31P NMR assignment of NADH–GA. 1H–13C long range correlation (HMBC)
are also reported (700 MHz, T = 5 C).
Position dH (ppm) dC (ppm) dP (ppm) HMBC
Adenine moiety




A-8 8.44 141.9 A-C4, A-C5
A-10 6.10 89,2 A-C8, A-C20
A-20 4.66 77,1 A-C10 , A-C40
A-30 4.46 72.6
A-40 4.35 86.0 A-C30
A-50 4.18–4.23 67.4 A-C30
P 10.2
Nicotinamide moiety
N-2 7.12 142.1 N-C7, N-C4, N-C6, NC10
N-3 102.8
N-4 3.37 39.9 N-C3, N-C5, N-C6
N-5 4.47 104.6 N-C4, N-C6, N-C3
N-6 6.20 127.6 N-C10 , N-C2, N-C5, N-C4
N-7 174.8
N-8 3.85 76.4 N-C9, N-C4, N-C5
N-9 180.4
N-10 4.79 97.1 N-C20 , N-C6, N-C2
N-20 4.16 73.3
N-30 4.17 72.6
N-40 4.08 84.7 N-C30
N-50 4.05–4.10 68.3
P 10.2
The table shows the NMR assignments for NADH–GA with the ﬁnal structure shown
in Fig. 1A.the addition of two carbon, three oxygen, and two hydrogen atoms
to NADH. In order to deﬁne the molecular structure of the puriﬁed
inhibitor 1D 1H and 31P NMR spectra, and 2D correlated spectros-
copy (COSY), 2D total correlated spectroscopy (TOCSY), 2D HSQC,
and 2D HMBC NMR data were collected. The analysis of the afore-
mentioned experiments allowed us to assign all the 1H, 13C, and 31P
resonances of the molecule (Table 1). The NMR results presented in
Table 1 along with the HRMS data led us to conclude that the
inhibitor originates from the covalent attachment of a glycolic acid
(GA) moiety to the C-4 position of the nicotinamide ring (Fig. 1A)
and that the inhibitor is essentially pure. In the present study the
inhibitor is referred to as NADH–GA.
The UV/Vis absorption spectrum of NADH–GA is shown in
Fig. 1B. The shape of the spectrum resembles that of authentic
NADH in the reduced state. NADH has absorption peaks at
260 nm and 340 nm, while the oxidized form (NAD+) only absorbs
at 260 nm. The presence of the peak at 327 nm in Fig. 1B is consis-
tent with the NMR data, demonstrating that the nicotinamide res-
idue in NADH–GA is reduced. The inhibitor is stable at neutral pH
as incubation of NADH–GA at 4 C for 6 days does not result in any
noticeable change of the absorption spectrum or the ability of the
inhibitor to suppress the activity of LDH. Incubation of the inhibi-
tor at 37 C resulted in a slow (half-time of 20 hours) reduction of
the absorption at 327 nm and a corresponding decrease in inhibi-
tion potency (data not shown).
Addition of 0.2 lMNADH–GA in the LDH assay results in a rapid
(several seconds) and almost complete suppression of enzyme
activity (Fig. 2, trace 1). The NAD+ utilizing enzyme MDH is also
partially inhibited by NADH–GA (Fig. 2, trace 2) although ﬁve times
the amount of the inhibitor is required to suppress MDH activity to
the same extent as that of LDH (data not shown). Other NAD+/
NADH utilizing enzymes were also investigated. It was found that
10 lMNADH–GA had no detectable effect on the activity of alcohol
dehydrogenase, glutamate dehydrogenase, DT-diaphorase, and
NADH oxidase activity catalyzed by bovine heart SMP. These re-
sults are consistent with the remarkable similarity in the con-
served functional active site amino acids, the nature of the
substrates and catalytic mechanism of LDH and MDH [24–26].
The other dehydrogenases tested here are less similar to LDH com-
pared to MDH and would be expected to be less sensitive to an LDH
inhibitor.
Preincubation of LDH with NADH–GA prior to initiation of the
reaction results in complete inhibition of the initial rate of NADH
oxidation followed by a relatively slow activation of the enzyme
(Fig. 3A). The slow activation (slow release of the inhibitor) in-
duced by addition of NADH into the assay is consistent with com-
petitive inhibition with very high afﬁnity. The inhibition measured
here using kinetic analysis by the Dixon method appears to be in
the range of a Ki of 4 nM, however, this value is most likely over-
estimated as a result of the tight-binding nature of the inhibitor.
Decreasing the incubation temperature from 25 to 10 C slows
down the rate of activation (Fig. 3A, compare traces 1 and 2). En-
zyme activation at 10 C is slow enough to permit accurate estima-
tion of the activation rate and initial rates of the reaction catalyzed
by the partially inhibited enzyme using conventional absorption
spectroscopy. The ﬁrst order kinetics of enzyme activation at
10 C yielded an activation constant (koff) of 1 min1 (inset to
Fig. 3A). Fig. 3B presents the dependence of the initial rate of the
reaction (10 C) on the concentration of NADH–GA in the incuba-
tion. As seen in Fig. 3B, the initial rate of the reaction, which is pro-
portional to the concentration of free (non-inhibited enzyme),
decreases linearly with the amount of inhibitor added. Almost
complete inhibition of the initial rate was achieved by addition
of 60 ll of NADH–GA from a stock solution to 1 ml of 0.6 mg/
ml LDH (see Fig. 3B). This end point on the titration curve
corresponds to equal concentrations of the inhibitor and the LDH
Fig. 1. Molecular structure and absorption properties of NADH–GA. (A) Molecular structure of NADH–GA. The glycolic acid moiety added to the authentic NADH molecule is
indicated by the dashed circle. (B) Absorption spectrum of NADH–GA.
Fig. 2. Kinetics of NADH–GA induced inhibition of LDH and MDH. LDH (trace 1) and
MDH (trace 2) were assayed in 100 mM K-Pi (pH 7.0), 0.1 mM EDTA and 140 lM
NADH as described in Section 2. Addition of 0.2 lM NADH–GA to the assay is
indicated by the arrow.
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spectrophotometrically using the molecular extinction of
50 mM1 cm1 at 280 nm [27,28] and is equal to 19.2 lM. It
has been shown that the four coenzyme binding sites of the LDH
tetramer are equal and independent [29], suggesting that all four
active sites of the enzyme are equivalent with respect to inhibitor
binding. The absorption of the inhibitor in the complex at 327 nm
is equal to 0.125 corresponding to the extinction coefﬁcient of
NADH–GA of 6.5 ± 0.5 mM1 cm1. This value is similar to that of
NADH and its derivatives in the near-UV spectral region [7,8,30].
Fig. 4A shows the results of treating cultured adult mouse car-
diac myocytes with varying concentrations of NADH–GA ranging
from 10 nM to 1 lM during 16 h of reoxygenation following 3
hours of hypoxia. Control cells were incubated under normoxic
conditions for the duration of the experiment and are assigned a
survival of 100%. Hypoxia/reoxygenation reduced myocyte survival
in the untreated control cells to less than 70%, while treatment
with NADH–GA improved viability as measured by trypan blue
exclusion to 85–90%. These observations demonstrate that as little
as 10 nM NADH–GA is sufﬁcient to promote cell survival underconditions of oxidative stress. As noted in the ﬁgure legend 1 nM
NADH–GA or concentrations above 2.5 lM did not result in signif-
icantly increased viability of cells following hypoxia/reoxygena-
tion. As shown in Fig. 4B, infusion of NADH–GA at a
concentration of 100 nM starting at the end of ischemia and
continuing throughout the entire 40 min of reperfusion resulted
in an almost threefold improvement in left ventricular developed
pressure at the end of reperfusion. Concurrently infarct size was
reduced by an average of 44% compared to vehicle-treated hearts.
These data indicate that the inhibitor exerted a substantial prosur-
vival effect in the ex vivo mouse heart by markedly improving
hemodynamic recovery and reducing the extent of tissue damage.
These observations are consistent with the prosurvival effects
noted in cultured adult mouse cardiac myocytes subjected to oxi-
dative stress (Fig. 4A).
4. Discussion
There has been intense interest in the prevention and treatment
of acute I/R injury which results in both short- and long-term dam-
age to heart muscle and which is considered to be the pathophys-
iology underlying acute myocardial infarction in humans [31].
When coronary blood ﬂow is reduced or ceases, aerobic processing
of metabolites via the Krebs cycle is markedly impaired and glyco-
lytic production of pyruvate is rapidly converted to lactate via acti-
vation of LDH. Accumulation of lactate during the ischemic phase
results in tissue and cellular acidosis [31]. Thus, it was of interest
to test the efﬁcacy of a potent stable LDH inhibitor in promoting
survival in cultured cardiac myocytes and reducing myocardial
infarction size in isolated hearts subjected to oxidative injury.
Fig. 4A shows that submicromolar concentrations of NADH–GA
protects cardiomyocytes from damage caused by oxidative stress.
The addition of the inhibitor to the perfusate following 40 min of
global ischemia also signiﬁcantly protects mouse hearts from I/R
damage (Fig. 4B). Although the precise mechanism leading to the
development of tissue injury during I/R is still not fully understood,
it is generally accepted that lactic acidosis is one of the factors
causing cell injury [32]. During ischemia anaerobic glycolysis be-
comes the main pathway supplying the cell with energy [33].
The end product of glycolysis, pyruvate, is converted to lactate in
the reaction catalyzed by LDH. It is known that during ischemia
Fig. 3. Inhibition of LDH by NADH–GA. (A) LDH (0.6 mg/ml) was incubated with 20 lM NADH–GA (traces 1 and 2) and without the inhibitor (traces 3 and 4) for 10 min at
25 C; aliquots were withdrawn from incubation mixtures and as assayed described in experimental procedures at 25 (traces 1 and 3) and at 10 C (traces 2 and 4). Three
times the amount of the enzyme was added to the assay when the reaction was carried out at 10 C compared to the reaction carried out at 25 C. The insert shows analysis of
the time dependence of the reaction rate measured at 10 C in a semi-logarithmic plot; the activation constant (koff) is equal to 1 min1. (B) – NADH–GA was added from the
stock solution to 1 ml of LDH (0.6 mg/ml) in 0.1 M K-Pi (pH 7.0) at quantities indicated (in ll) on the x-axes and incubated for 10 min at 25 C; aliquots were withdrawn from
the incubation and as assayed described in (A) at 10 C. The dependence of the initial rate of the reaction measured 3–4 s after the addition of the enzyme and plotted as a
function of NADH–GA concentration in the incubation.
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cellular pH [34]. The increase in proton concentration initiates a
cascade of events leading to apoptosis and cell death in cultured
cells including cardiac myocytes [14,15,17,35,36]. Earlier studies
had shown that 3-acetylpyridine nicotinamide adenine dinucleo-
tide-pyruvate (ANAD-Pyr), a strong inhibitor of LDH, reduced lac-
tate production in crude brain extracts, although the inhibitor
was less effective in synaptosomes [9]. The main reason for the
minimal effect in synaptosomes is likely associated with the
hydrophilic nature of ANAD-Pyr and the low stability of the com-
pound at physiological pH [9]. NADH–GA is also highly polar and
very stable under physiological conditions and in contrast to
ANAD-Pyr can not be degraded by LDH. This may be the reason
that NADH–GA is protective in both cardiomyocytes and in an
ex vivo model of I/R injury (see Fig. 4). The expected slow rate of
NADH–GA passive transport through the cell membrane is a disad-
vantage, which could reduce the inhibitor efﬁciency limiting its
application as cardioprotective agent. Attachment of hydrophobic
residues by covalent modiﬁcation of the ribose portion of the
inhibitor should strongly increase its permeability through the cell
membrane and might lead to a increase of the cardioprotective ef-
fect of the inhibitor.The cardioprotective mechanism of NADH–GA may, however,
not be directly related to inhibition of lactic acid production since
NADH–GA was added during the reperfusion phase. It is known
that restoration of blood ﬂow to the ischemic region during I/R
leads to a further increase in tissue damage beyond that caused
by ischemia alone [37–43]. The damage during the reperfusion
phase is due, in large part, to the generation of reactive oxygen spe-
cies (ROS). It has been demonstrated that ROS concentration is
strongly increased in the myocardium during early reperfusion
[44–48]. As shown in Fig. 4B, NADH–GA added at the time of reper-
fusion restores mechanical function and reduces infarct size in a
Langendorff perfused mouse heart model. The mitochondrial respi-
ratory chain is an important source of ROS originating during the
ﬁrst minutes of reperfusion. One may speculate that lactic acid
accumulated in large quantities during the ischemic phase may
serve as a source of reducing equivalents for the respiratory chain,
thus contributing to ROS formation. Lactic acid accumulated dur-
ing ischemia can be converted to pyruvate by LDH (the reverse
reaction) and further metabolized by the citric acid cycle yielding
NADH. Subsequent oxidation of NADH by mitochondrial respira-
tory complexes could also lead to ROS formation. Inhibition of
LDH by NADH–GA will slow pyruvate formation from lactate and
Fig. 4. Protective effect of NADH–GA on cardiac myocytes and on mouse heart. (A) Viability of cultured adult mouse cardiac myocytes was measured by trypan blue
exclusion. The lactate dehydrogenase inhibitor NADH–GA was added to the cultures at the beginning of reoxygenation in a room air incubator exhibited signiﬁcant
cytoprotection between 10 nM and 1 lM. Several trials were also done with concentrations as low as 1 nM to as high as 2.5 lM of NADH–GA, however, no statistically
signiﬁcant effects on viability were noted at these concentrations (data not shown). For a baseline reference, cells were continuously incubated under normoxic conditions.
Data are mean ± S.E.M. and are from a minimum of ﬁve separate experiments for each concentration tested. Control was considered to be 100% for each experiment. Statistical
analysis was by ANOVA with Neuman–Keuls post hoc testing. *P < 0.05 vs. all other conditions. Light gray bar (Con) is normoxic control, dark gray bar (Con) is hypoxic control.
(B) Adult mouse hearts were mounted on a Langendorff rig and after 20 min of equilibration were subjected to 40 min of global ischemia followed by 45 min of reperfusion.
Hearts were treated or not with 100 nM NADH–GA at the end of ischemia and infusion was continued throughout reperfusion. The left panel shows improved recovery of left
ventricular developed pressure at the end of reperfusion in hearts treated with NADH–GA. The right panel shows that NADH–GA also signiﬁcantly reduced infarct size in
these hearts. Data are mean SEM, *P < 0.05 vs. control and are from 5 to 7 separate experiments. LVDP = left ventricular developed pressure; RA = risk area.
164 A.B. Kotlyar et al. / FEBS Letters 584 (2010) 159–165as a result will suppress ROS formation. This would prevent tissue
damage caused by free radicals and would be consistent with the
protective effect of NADH–GA reported here.
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